희귀의약품 시장 : 질병 유형, 제품 유형, 유통 채널별 - 세계 예측(2025-2030년)

The Orphan Drugs Market was valued at USD 191.86 billion in 2023, expected to reach USD 216.80 billion in 2024, and is projected to grow at a CAGR of 13.39%, to USD 462.45 billion by 2030.

Orphan drugs, specifically designed to treat rare diseases affecting a small percentage of the population, play a critical role in addressing unmet medical needs. These conditions often lack effective treatments due to their rarity, making orphan drugs an essential focus in the pharmaceutical industry. The market for these drugs is driven by the urgent necessity to provide therapies for rare diseases and is characterized by an increasing number of regulatory incentives like market exclusivity and tax credits. The primary application of orphan drugs spans across genetic disorders, rare cancers, and other rare conditions, with significant end-use in hospitals, clinics, and specialty pharmacies. Market growth is propelled by technological advancements in biotechnology, active support from regulatory bodies, and the heightened focus on personalized medicine. Nonetheless, challenges such as high development costs, lengthy approval processes, and limited patient pools can hinder progress. The market is burgeoning with potential opportunities, namely the expansion into emerging markets with untapped healthcare needs, and strategic collaborations for research and development activities. Companies can capitalize on opportunities by investing in gene therapy, personalized medicine, and adaptive clinical trial designs which can reduce the time and cost associated with drug development. However, firms must navigate through complex regulatory landscapes and ethical considerations. Innovations should primarily focus on precision medicine and the integration of AI and big data analytics to streamline drug discovery and development. Research should also emphasize the exploration of novel pathways and targets for rare disorders. The nature of this market is progressively dynamic, with a trend toward patient-centric care and regulatory frameworks being more accommodating for expedited drug development. Businesses that adapt to these trends and invest in strategic partnerships are likely to gain a competitive edge in this niche but rapidly evolving sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Orphan Drugs Market

The Orphan Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surge in prevalence of rare diseases and increasing healthcare expenditure
  • Favorable government and economic incentives for the development of drugs for rare diseases
  • Availability of exclusivity for orphan drugs
• Market Restraints
  • High cost associated with orphan drugs
• Market Opportunities
  • Increasing R&D initiatives and development of novel products
  • Regulatory incentives for the development of orphan drugs in emerging countries
• Market Challenges
  • Side effects associated with orphan drugs

Porter's Five Forces: A Strategic Tool for Navigating the Orphan Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Orphan Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Orphan Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Orphan Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Orphan Drugs Market

A detailed market share analysis in the Orphan Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Orphan Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Orphan Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Orphan Drugs Market

A strategic analysis of the Orphan Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Orphan Drugs Market, highlighting leading vendors and their innovative profiles. These include Alexion Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Belite Bio Inc, Biogen Inc., Dynacure SA, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., MeiraGTx Limited, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Orphan Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Gastrointestinal, Hematology, Infectious Diseases, Neurology, Oncology, and Pulmonary.
• Based on Product Type, market is studied across Biologic and Non-Biologic.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surge in prevalence of rare diseases and increasing healthcare expenditure
    • 5.1.1.2. Favorable government and economic incentives for the development of drugs for rare diseases
    • 5.1.1.3. Availability of exclusivity for orphan drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with orphan drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing R&D initiatives and development of novel products
    • 5.1.3.2. Regulatory incentives for the development of orphan drugs in emerging countries
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with orphan drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Orphan Drugs Market, by Disease Type

• 6.1. Introduction
• 6.2. Gastrointestinal
• 6.3. Hematology
• 6.4. Infectious Diseases
• 6.5. Neurology
• 6.6. Oncology
• 6.7. Pulmonary

7. Orphan Drugs Market, by Product Type

• 7.1. Introduction
• 7.2. Biologic
• 7.3. Non-Biologic

8. Orphan Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Specialty Pharmacies

9. Americas Orphan Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Orphan Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Orphan Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alexion Pharmaceuticals, Inc.
• 2. AstraZeneca PLC
• 3. Bayer AG
• 4. Belite Bio Inc
• 5. Biogen Inc.
• 6. Dynacure SA
• 7. Eisai Co. Ltd.
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche Ltd
• 10. GlaxoSmithKline PLC
• 11. Johnson & Johnson Services, Inc.
• 12. MeiraGTx Limited
• 13. Novartis AG
• 14. Pfizer Inc.
• 15. Sanofi S.A.